SMARCD2

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 2 · Q92925 · SMARCD2 on Sugi Atlas →

0 patent compounds predicted against SMARCD2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SMARCD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) PHASE3RECRUITING
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE3ACTIVE_NOT_RECRUITING
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC PHASE2NOT_YET_RECRUITING
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer. PHASE2NOT_YET_RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) PHASE2COMPLETED
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. PHASE2RECRUITING
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer PHASE2RECRUITING
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer PHASE2ACTIVE_NOT_RECRUITING
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma PHASE1/PHASE2WITHDRAWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation PHASE1COMPLETED
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction PHASE1WITHDRAWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer PHASE1RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Implementation of FEES in Spinal Muscle Atrophy nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC nanNOT_YET_RECRUITING
Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer nanUNKNOWN
Natural History Study of Smith-Magenis Syndrome nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SMARCD2 binder may also engage these)

ProteinNameSimilarity
O54772 1.000 O54772 →
SMARCD1 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1 1.000 landscape →
Q6P9Z1 0.999 Q6P9Z1 →
E1BJD1 0.999 E1BJD1 →
Q61466 0.997 Q61466 →
Q99JR8 0.996 Q99JR8 →
Q2TBN1 0.996 Q2TBN1 →
Q6STE5 0.992 Q6STE5 →
Q9VYG2 0.990 Q9VYG2 →
Q96G25 0.987 Q96G25 →
Q9D7W5 0.987 Q9D7W5 →
Q27974 0.986 Q27974 →
Q9JJP2 0.985 Q9JJP2 →
Q5NBT9 0.984 Q5NBT9 →
O75061 0.984 O75061 →
KAT2A Histone acetyltransferase KAT2A 0.983 landscape →
Q0J7U6 0.983 Q0J7U6 →
Q09646 0.983 Q09646 →
Q62141 0.982 Q62141 →
Q294G7 0.982 Q294G7 →
Q96M27 0.982 Q96M27 →
Q80TJ1 0.981 Q80TJ1 →
Q8BHR2 0.981 Q8BHR2 →
O76808 0.981 O76808 →
P42768 0.981 P42768 →
Q80TZ3 0.981 Q80TZ3 →
Q95RR8 0.981 Q95RR8 →
Q5HZZ6 0.981 Q5HZZ6 →
A1XD97 0.981 A1XD97 →
Q90701 0.980 Q90701 →